ArticleDiscover oncology2025
Transcriptomic landscape of NK cell-related genes in hepatocellular carcinoma: associations with prognosis and therapeutic response.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a highly aggressive and heterogeneous malignancy, in which natural killer (NK) cells play a crucial role in tumor progression and immune surveillance. This study aimed to characterize the transcriptomic landscape of NK cell-associated genes (NAGs) and explore their associations with clinical outcomes and therapeutic responses in HCC. Using transcriptomic data from The Cancer Genome Atlas (TCGA), we identified key NAGs through comprehensive statistical analyses. Patients were stratified into distinct risk groups based on NAG expression profiles. Low-risk patients demonstrated better survival, higher immune infiltration, and greater predicted sensitivity to immunotherapy, whereas high-risk patients were associated with reduced chemotherapy responsiveness. These findings contribute to a deeper understanding of the immunogenomic features of HCC and provide a basis for developing personalized therapeutic approaches centered on NK cell-related mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.